Somewhat Favorable News Coverage Somewhat Unlikely to Impact Genomic Health (NASDAQ:GHDX) Share Price
Headlines about Genomic Health (NASDAQ:GHDX) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Genomic Health earned a coverage optimism score of 0.03 on Accern’s scale. Accern also gave news articles about the medical research company an impact score of 46.5091560602088 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the media stories that may have effected Accern’s scoring:
- Genomic Health, Inc. (GHDX) Expected to Post Quarterly Sales of $89.44 Million (americanbankingnews.com)
- Genomic Health, Inc. (NASDAQ:GHDX) Lowered to Sell at BidaskClub (americanbankingnews.com)
- Genomic Health, Inc. (GHDX) Earns Hold Rating from Piper Jaffray Companies (americanbankingnews.com)
- Genomic Health, Inc.: Still Waiting for Reimbursement (fool.com)
- Brokers Issue Forecasts for Genomic Health, Inc.’s Q3 2017 Earnings (GHDX) (americanbankingnews.com)
A number of equities research analysts have recently issued reports on the company. BidaskClub lowered Genomic Health from a “hold” rating to a “sell” rating in a research report on Friday. Zacks Investment Research downgraded Genomic Health from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. Piper Jaffray Companies reiterated a “hold” rating and set a $31.00 price target on shares of Genomic Health in a report on Thursday. Jefferies Group LLC reiterated a “hold” rating and set a $33.00 price target on shares of Genomic Health in a report on Monday, June 12th. Finally, Raymond James Financial, Inc. reiterated a “market perform” rating on shares of Genomic Health in a report on Wednesday, May 3rd. They noted that the move was a valuation call. Three analysts have rated the stock with a sell rating, five have assigned a hold rating and one has given a buy rating to the company. The company has an average rating of “Hold” and an average price target of $32.43.
Shares of Genomic Health (NASDAQ GHDX) traded up 2.29% on Monday, hitting $31.21. The stock had a trading volume of 28,703 shares. Genomic Health has a one year low of $25.66 and a one year high of $33.97. The firm has a 50 day moving average price of $32.69 and a 200 day moving average price of $31.05. The company’s market capitalization is $1.07 billion.
Genomic Health (NASDAQ:GHDX) last issued its quarterly earnings data on Tuesday, August 1st. The medical research company reported ($0.08) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by $0.02. The business had revenue of $85.50 million for the quarter, compared to analyst estimates of $86.08 million. Genomic Health had a negative return on equity of 4.44% and a negative net margin of 1.50%. The business’s quarterly revenue was up 4.3% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.18) EPS. On average, equities research analysts predict that Genomic Health will post $0.02 earnings per share for the current fiscal year.
In other Genomic Health news, CEO Kimberly J. Popovits sold 1,468 shares of Genomic Health stock in a transaction dated Wednesday, July 5th. The stock was sold at an average price of $32.67, for a total value of $47,959.56. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Steven Shak sold 5,000 shares of Genomic Health stock in a transaction dated Tuesday, May 23rd. The shares were sold at an average price of $29.40, for a total value of $147,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 62,642 shares of company stock worth $1,944,896 in the last ninety days. 46.20% of the stock is currently owned by company insiders.
WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact Genomic Health (NASDAQ:GHDX) Share Price” was posted by Daily Political and is the property of of Daily Political. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this report can be accessed at https://www.dailypolitical.com/2017/08/07/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-genomic-health-nasdaqghdx-share-price.html.
About Genomic Health
Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.
Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.